Kazuhiro Kajiyama
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kazuhiro Kajiyama has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Yoshiaki Uyama
Pharmaceuticals and Medical Devices Agency Tokyo Japan
5 shared publications Naoya Horiuchi
Office of Pharmacovigilance I Pharmaceuticals and Medical Devices Agency Tokyo Japan
3 shared publications- Tomoaki Hasegawa
Office of Pharmacovigilance I Pharmaceuticals and Medical Devices Agency Tokyo Japan
3 shared publications Toyotaka Iguchi
Office of Pharmacovigilance II Pharmaceuticals and Medical Devices Agency Tokyo Japan
3 shared publications- Chieko Ishiguro
Laboratory of Clinical Epidemiology, Department of Data Science, Center for Clinical Sciences Japan Institute for Health Security Tokyo Japan
2 shared publications - Shinya Watanabe
Office of Pharmacovigilance I Pharmaceuticals and Medical Devices Agency Tokyo Japan
2 shared publications
Latest Publications
- Open Access
- 21 November 2025
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 119 (3) , 721-728
Cardiovascular Risk of Romosozumab vs. Teriparatide: A Cohort Study Using Japan’s National Claims Database
Disproportionality analyses suggested a cardiovascular risk signal for romosozumab, while statistically significant associations were not found in the real‐world database studies. Therefore, a larger comparative study was necessary to examine this signal. This study aimed to compare the cardiovascular risks of romosozumab with those of teriparatide in the overall population and in groups with a history of major adverse cardiovascular events (MACE). A new user cohort study was conducted using Japan’s national claims database. Patients aged ≥ 40 years who initiated romosozumab or teriparatide between March 2019 and March 2023 were analyzed. A multivariable Cox proportional hazards model was used to estimate the adjusted hazard ratio (aHR) for MACE. Subgroup analyses were conducted based on MACE history. A total of 251,219 romosozumab and 500,445 teriparatide users were analyzed (most common age group was 80–89 years for both drugs; men: 9.33% for romosozumab and 14.14% for teriparatide). MACE occurred in 1853 romosozumab and 3427 teriparatide users, with incidence rates of 1.09 and 1.22 per 100 person‐years, respectively. The aHR (95% confidence interval [CI]) for romosozumab compared with teriparatide was 1.00 (0.94–1.06). In subgroup analyses based on MACE history, the aHRs (95% CI) for no history, for the one‐year period leading up to t 0 , and for more than 1 year before t 0 were 1.01 (0.95–1.08), 0.93 (0.72–1.21), and 1.00 (0.85–1.18), respectively. In conclusion, no statistically significant difference in MACE risk was observed between romosozumab and teriparatide in Japan’s national claims database, regardless of MACE history.
- 21 November 2025
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 119 (3) , 721-728
Open AccessCardiovascular Risk of Romosozumab vs. Teriparatide: A Cohort Study Using Japan’s National Claims Database
Disproportionality analyses suggested a cardiovascular risk signal for romosozumab, while statistically significant associations were not found in the real‐world database studies. Therefore, a larger comparative study was necessary to examine this signal. This study aimed to compare the cardiovascular risks of romosozumab with those of teriparatide in the overall population and in groups with a history of major adverse cardiovascular events (MACE). A new user cohort study was conducted using Japan’s national claims database. Patients aged ≥ 40 years who initiated romosozumab or teriparatide between March 2019 and March 2023 were analyzed. A multivariable Cox proportional hazards model was used to estimate the adjusted hazard ratio (aHR) for MACE. Subgroup analyses were conducted based on MACE history. A total of 251,219 romosozumab and 500,445 teriparatide users were analyzed (most common age group was 80–89 years for both drugs; men: 9.33% for romosozumab and 14.14% for teriparatide). MACE occurred in 1853 romosozumab and 3427 teriparatide users, with incidence rates of 1.09 and 1.22 per 100 person‐years, respectively. The aHR (95% confidence interval [CI]) for romosozumab compared with teriparatide was 1.00 (0.94–1.06). In subgroup analyses based on MACE history, the aHRs (95% CI) for no history, for the one‐year period leading up to t 0 , and for more than 1 year before t 0 were 1.01 (0.95–1.08), 0.93 (0.72–1.21), and 1.00 (0.85–1.18), respectively. In conclusion, no statistically significant difference in MACE risk was observed between romosozumab and teriparatide in Japan’s national claims database, regardless of MACE history.
- Open Access
- 6 June 2025
- Published by Wiley in Clinical and Translational Science
- Vol. 18 (6) , e70268
Risk of Thrombocytopenia by SSRIs or SNRIs in Patients With Depression Based on MID‐NET: A Cohort Study in Japan
Risk assessment on thrombocytopenia by selective serotonin reuptake inhibitors (SSRIs) or serotonin noradrenaline reuptake inhibitors (SNRIs) is limited. An observational study with cohort design was conducted based on the MID‐NET for evaluating the risk of thrombocytopenia by SSRIs and SNRIs in patients with depression compared to paroxetine. The exposure group was categorized as each drug of SSRIs/SNRIs, SSRIs group (escitalopram, sertraline, fluvoxamine), SNRIs group (duloxetine, venlafaxine, milnacipran), or vortioxetine. We estimated the adjusted hazard ratio (aHR) of each drug compared to paroxetine for the risk of thrombocytopenia (platelet count < 100,000/mm3). More severe definitions were used in sensitivity analyses. In all, 4759 patients (median age: 49 years; 31.6% male) on SSRIs, 3440 patients (62 years; 38.6% male) on SNRIs, 12 patients (42.5 years; less than 83.4% male) on vortioxetine, and 2196 patients on paroxetine (62 years; 33.2% male) were included for analysis. Compared with paroxetine, the aHRs (95% confidence interval) of SSRIs group and SNRIs group were 1.14 (0.76–1.70) and 0.77 (0.48–1.21), respectively. Among SSRIs, sertraline and fluvoxamine showed a relatively higher point estimate of aHR > 1.0 (1.23 [95% confidence interval: 0.78–1.94] and 1.48 [0.87–2.51], respectively). The consistent results were also observed in the sensitivity analyses. The results suggest that the risk of thrombocytopenia by sertraline or fluvoxamine was comparable to that by paroxetine, known as having the risk of thrombocytopenia, leading to the revision of the sertraline package insert as a regulatory safety measure. Prescribers and clinicians may need to be vigilant to the possibility of sertraline‐induced thrombocytopenia in clinical practice.
- 6 June 2025
- Published by Wiley in Clinical and Translational Science
- Vol. 18 (6) , e70268
Open AccessRisk of Thrombocytopenia by SSRIs or SNRIs in Patients With Depression Based on MID‐NET: A Cohort Study in Japan
Risk assessment on thrombocytopenia by selective serotonin reuptake inhibitors (SSRIs) or serotonin noradrenaline reuptake inhibitors (SNRIs) is limited. An observational study with cohort design was conducted based on the MID‐NET for evaluating the risk of thrombocytopenia by SSRIs and SNRIs in patients with depression compared to paroxetine. The exposure group was categorized as each drug of SSRIs/SNRIs, SSRIs group (escitalopram, sertraline, fluvoxamine), SNRIs group (duloxetine, venlafaxine, milnacipran), or vortioxetine. We estimated the adjusted hazard ratio (aHR) of each drug compared to paroxetine for the risk of thrombocytopenia (platelet count < 100,000/mm3). More severe definitions were used in sensitivity analyses. In all, 4759 patients (median age: 49 years; 31.6% male) on SSRIs, 3440 patients (62 years; 38.6% male) on SNRIs, 12 patients (42.5 years; less than 83.4% male) on vortioxetine, and 2196 patients on paroxetine (62 years; 33.2% male) were included for analysis. Compared with paroxetine, the aHRs (95% confidence interval) of SSRIs group and SNRIs group were 1.14 (0.76–1.70) and 0.77 (0.48–1.21), respectively. Among SSRIs, sertraline and fluvoxamine showed a relatively higher point estimate of aHR > 1.0 (1.23 [95% confidence interval: 0.78–1.94] and 1.48 [0.87–2.51], respectively). The consistent results were also observed in the sensitivity analyses. The results suggest that the risk of thrombocytopenia by sertraline or fluvoxamine was comparable to that by paroxetine, known as having the risk of thrombocytopenia, leading to the revision of the sertraline package insert as a regulatory safety measure. Prescribers and clinicians may need to be vigilant to the possibility of sertraline‐induced thrombocytopenia in clinical practice.
- Open Access
- 2 April 2025
- Published by Wiley in Clinical and Translational Science
- Vol. 18 (4) , e70208
New Function for Safety Signal Monitoring in MID‐NET®: The Case of an Anti‐COVID‐19 Drug
Real‐world data play a key role in monitoring drug safety at the post‐marketing stage. However, challenges on how to rapidly and continuously obtain analytical results of many outcomes for drug safety signal monitoring still remain. We aimed to establish a rapid and continuous monitoring tool for drug safety assessment based on real‐world data in Japan. An automated process for a new‐user cohort design with customizable analytical conditions was developed. The customizable analytical conditions include exposure and control drugs, 46 outcomes related to liver and kidney functions, blood tests, biomarkers, and time period of interest. Statistical analyses were performed to evaluate the outcome status (present/absent) and calculate the adjusted hazard ratio, with a 95% confidence interval of exposure to control. We monitored the safety signals of an anti‐COVID‐19 drug (combination of tixagevimab and cilgavimab) and compared them with those of two controls (peramivir and the combination of casirivimab and imdevimab) to examine the practical utility of this new tool. Our study provided helpful information (e.g., new safety signals) on many outcomes at multiple time points, which could enhance the understanding of drug safety profiles soon after approval. Our function can be used to rapidly and continuously monitor drug safety signals and contribute to strengthening drug safety monitoring in Japan.
- 2 April 2025
- Published by Wiley in Clinical and Translational Science
- Vol. 18 (4) , e70208
Open AccessNew Function for Safety Signal Monitoring in MID‐NET®: The Case of an Anti‐COVID‐19 Drug
Real‐world data play a key role in monitoring drug safety at the post‐marketing stage. However, challenges on how to rapidly and continuously obtain analytical results of many outcomes for drug safety signal monitoring still remain. We aimed to establish a rapid and continuous monitoring tool for drug safety assessment based on real‐world data in Japan. An automated process for a new‐user cohort design with customizable analytical conditions was developed. The customizable analytical conditions include exposure and control drugs, 46 outcomes related to liver and kidney functions, blood tests, biomarkers, and time period of interest. Statistical analyses were performed to evaluate the outcome status (present/absent) and calculate the adjusted hazard ratio, with a 95% confidence interval of exposure to control. We monitored the safety signals of an anti‐COVID‐19 drug (combination of tixagevimab and cilgavimab) and compared them with those of two controls (peramivir and the combination of casirivimab and imdevimab) to examine the practical utility of this new tool. Our study provided helpful information (e.g., new safety signals) on many outcomes at multiple time points, which could enhance the understanding of drug safety profiles soon after approval. Our function can be used to rapidly and continuously monitor drug safety signals and contribute to strengthening drug safety monitoring in Japan.
- Open Access
- 1 December 2024
- Published by Wiley in Clinical and Translational Science
- Vol. 17 (12) , e70096
Risk of artery dissection during systemic exposure to vascular endothelial growth factor pathway inhibitors
Whether or not vascular endothelial growth factor pathway inhibitors (VPIs) increase the risk of artery dissection is still unknown. This study aimed to quantitatively evaluate the possibility of artery dissection as a class effect of VPIs using nationwide real‐world data. This cohort study was conducted based on the National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB), which spans nearly the entire Japanese population of over 100 million individuals. We included the patients prescribed with 12 types of VPIs between 2012 and 2020. The incidence rate (IR) ratio of artery dissection for each VPI were estimated in comparison with bevacizumab, the only VPI in Japan with artery dissection listed in the package insert. Artery dissection as an outcome was targeted for acute artery dissection requiring hospitalization (including dissecting aneurysm). As a reference, a natural IR standardized by sex and age of bevacizumab‐prescribed patients was also estimated using the direct method for the general population of NDB. Of 503,342 patients, the IR of artery dissection for bevacizumab was 44.4 (/100,000 person‐years), and the adjusted IR ratios for each VPI compared with bevacizumab were consistently similar to or >1.0. The IRs for each VPI were also higher than the crude natural IR (1.66/100,000 person‐years; 95% CI: 1.59–1.73) and the standardized natural IR (2.18/100,000 person‐years; 95% CI: 1.86–2.50). Real‐world evidence suggests the risk of artery dissection as a class effect of VPIs. More attention on this risk will be necessary when using VPIs in clinical practice.
- 1 December 2024
- Published by Wiley in Clinical and Translational Science
- Vol. 17 (12) , e70096
Open AccessRisk of artery dissection during systemic exposure to vascular endothelial growth factor pathway inhibitors
Whether or not vascular endothelial growth factor pathway inhibitors (VPIs) increase the risk of artery dissection is still unknown. This study aimed to quantitatively evaluate the possibility of artery dissection as a class effect of VPIs using nationwide real‐world data. This cohort study was conducted based on the National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB), which spans nearly the entire Japanese population of over 100 million individuals. We included the patients prescribed with 12 types of VPIs between 2012 and 2020. The incidence rate (IR) ratio of artery dissection for each VPI were estimated in comparison with bevacizumab, the only VPI in Japan with artery dissection listed in the package insert. Artery dissection as an outcome was targeted for acute artery dissection requiring hospitalization (including dissecting aneurysm). As a reference, a natural IR standardized by sex and age of bevacizumab‐prescribed patients was also estimated using the direct method for the general population of NDB. Of 503,342 patients, the IR of artery dissection for bevacizumab was 44.4 (/100,000 person‐years), and the adjusted IR ratios for each VPI compared with bevacizumab were consistently similar to or >1.0. The IRs for each VPI were also higher than the crude natural IR (1.66/100,000 person‐years; 95% CI: 1.59–1.73) and the standardized natural IR (2.18/100,000 person‐years; 95% CI: 1.86–2.50). Real‐world evidence suggests the risk of artery dissection as a class effect of VPIs. More attention on this risk will be necessary when using VPIs in clinical practice.
- Open Access
- 31 January 2023
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 113 (4) , 924-931
Characterizing Granulocytopenia Associated with Thiamazole in Patients with Hyperthyroidism Based on Real‐World Data from the MID‐NET in Japan
Despite the requirement of routine blood tests during thiamazole treatment in Japan, granulocytopenia among patients treated with thiamazole has been occasionally reported to the Pharmaceuticals and Medical Devices Agency (PMDA). To characterize granulocytopenia in patients with thiamazole in Japan, the effects of routine blood tests were examined in a cohort of new users of thiamazole or propylthiouracil utilizing the MID‐NET. The occurrence of granulocytopenia (neutrophil count ≤ 1,500/μL) in a given period was compared between patients with and without blood test results prior to the period. The trend in neutrophil count during thiamazole treatment was also compared between patients with and without granulocytopenia. A nested case–control study based on the cohort was conducted to identify potential risk factors for granulocytopenia during thiamazole treatment. In the new user cohort including 4,371 patients treated with thiamazole, the occurrence of granulocytopenia in patients who had undergone blood tests at all previous periods was similar or higher than that among those who had not undergone blood test in all previous periods (e.g., adjusted odds ratio in period 2 was 1.63). The neutrophil count was relatively lower in the group of patients with granulocytopenia even before the occurrence of granulocytopenia. In a nested case–control study, an upward tendency of the risk was observed when a patient was co‐prescribed anti‐arrhythmic drugs or antiulcer drugs with thiamazole. The characteristics of granulocytopenia during thiamazole treatment elucidated in this study should be recognized in clinical practice for the proper use of thiamazole.
- 31 January 2023
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 113 (4) , 924-931
Open AccessCharacterizing Granulocytopenia Associated with Thiamazole in Patients with Hyperthyroidism Based on Real‐World Data from the MID‐NET in Japan
Despite the requirement of routine blood tests during thiamazole treatment in Japan, granulocytopenia among patients treated with thiamazole has been occasionally reported to the Pharmaceuticals and Medical Devices Agency (PMDA). To characterize granulocytopenia in patients with thiamazole in Japan, the effects of routine blood tests were examined in a cohort of new users of thiamazole or propylthiouracil utilizing the MID‐NET. The occurrence of granulocytopenia (neutrophil count ≤ 1,500/μL) in a given period was compared between patients with and without blood test results prior to the period. The trend in neutrophil count during thiamazole treatment was also compared between patients with and without granulocytopenia. A nested case–control study based on the cohort was conducted to identify potential risk factors for granulocytopenia during thiamazole treatment. In the new user cohort including 4,371 patients treated with thiamazole, the occurrence of granulocytopenia in patients who had undergone blood tests at all previous periods was similar or higher than that among those who had not undergone blood test in all previous periods (e.g., adjusted odds ratio in period 2 was 1.63). The neutrophil count was relatively lower in the group of patients with granulocytopenia even before the occurrence of granulocytopenia. In a nested case–control study, an upward tendency of the risk was observed when a patient was co‐prescribed anti‐arrhythmic drugs or antiulcer drugs with thiamazole. The characteristics of granulocytopenia during thiamazole treatment elucidated in this study should be recognized in clinical practice for the proper use of thiamazole.
- 23 July 2019
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 28 (9) , 1166-1174
Cardiovascular risks associated with dipeptidyl peptidase‐4 inhibitors monotherapy compared with other antidiabetes drugs in the Japanese population: A nationwide cohort study
Purpose: We evaluated the cardiovascular risk associated with dipeptidyl peptidase‐4 inhibitors (DPP‐4Is) as monotherapy compared with other antidiabetic drugs in Japan.Methods: We conducted a nationwide cohort study involving 2 716 000 diabetes patients in Japan. New users of any antidiabetic drug as monotherapy between 1 April 2010 and 31 October 2014 were identified. Occurrences of myocardial infarction (MI), heart failure (HF), and stroke requiring hospitalization associated with DPP‐4Is were compared with those associated with biguanides (BGs), sulfonylureas (SUs), or α‐glucosidase inhibitors (α‐GIs). Adjusted hazard ratios (aHRs) for these outcomes were estimated by Cox proportional hazards model. Propensity score standardization was used to control for confounding.Results: We identified 1 105 103 patients using DPP‐4Is, 278 280 patients using BGs, 273 449 patients using SUs, and 217 026 patients using α‐GIs. The risks of MI and HF for DPP‐4I users were significantly higher than those for BG users (MI: aHR, 1.48 [95%CI, 1.20‐1.82], HF: aHR, 1.46 [95%CI, 1.31‐1.62]), while significantly lower than those for SU users (MI: aHR, 0.84 [95%CI, 0.72‐0.98], HF: aHR, 0.86 [95%CI, 0.81‐0.92]). The risk of MI for DPP‐4I users was similar to that for α‐GI users, while the risk of HF for DPP‐4I users was slightly higher than for α‐GI users (MI: aHR, 0.98 [95%CI, 0.82‐1.17], HF: aHR, 1.12[95%CI, 1.04‐1.21]).Conclusions: Risk of MI and HF requiring hospitalization associated with DPP‐4Is as monotherapy was significantly higher than BGs, significantly lower than SUs, and similar to α‐GIs.
- 23 July 2019
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 28 (9) , 1166-1174
Cardiovascular risks associated with dipeptidyl peptidase‐4 inhibitors monotherapy compared with other antidiabetes drugs in the Japanese population: A nationwide cohort study
Purpose: We evaluated the cardiovascular risk associated with dipeptidyl peptidase‐4 inhibitors (DPP‐4Is) as monotherapy compared with other antidiabetic drugs in Japan.Methods: We conducted a nationwide cohort study involving 2 716 000 diabetes patients in Japan. New users of any antidiabetic drug as monotherapy between 1 April 2010 and 31 October 2014 were identified. Occurrences of myocardial infarction (MI), heart failure (HF), and stroke requiring hospitalization associated with DPP‐4Is were compared with those associated with biguanides (BGs), sulfonylureas (SUs), or α‐glucosidase inhibitors (α‐GIs). Adjusted hazard ratios (aHRs) for these outcomes were estimated by Cox proportional hazards model. Propensity score standardization was used to control for confounding.Results: We identified 1 105 103 patients using DPP‐4Is, 278 280 patients using BGs, 273 449 patients using SUs, and 217 026 patients using α‐GIs. The risks of MI and HF for DPP‐4I users were significantly higher than those for BG users (MI: aHR, 1.48 [95%CI, 1.20‐1.82], HF: aHR, 1.46 [95%CI, 1.31‐1.62]), while significantly lower than those for SU users (MI: aHR, 0.84 [95%CI, 0.72‐0.98], HF: aHR, 0.86 [95%CI, 0.81‐0.92]). The risk of MI for DPP‐4I users was similar to that for α‐GI users, while the risk of HF for DPP‐4I users was slightly higher than for α‐GI users (MI: aHR, 0.98 [95%CI, 0.82‐1.17], HF: aHR, 1.12[95%CI, 1.04‐1.21]).Conclusions: Risk of MI and HF requiring hospitalization associated with DPP‐4Is as monotherapy was significantly higher than BGs, significantly lower than SUs, and similar to α‐GIs.